The first 60 days: Essential thrombocythaemia (ET)
Essential thrombocythaemia is a slow blood cancer in which the marrow makes too many platelets. Most people need only aspirin and monitoring; those at higher risk of clots take a drug to lower the platelet count, usually hydroxyurea or interferon, with anagrelide in reserve. Below, week by week, is what OnCo's record of Essential thrombocythaemia (ET) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Full blood count, JAK2, CALR and MPL testing, bone marrow biopsy to confirm ET and exclude prefibrotic myelofibrosis, and exclusion of reactive causes (iron deficiency, inflammation, infection, splenectomy).
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Diagnosis.
- SurgeonNamed in the standard of care for: Diagnosis.
- Medical oncologistNamed in the standard of care for: Very low and low risk, High risk (over 60 with JAK2 or prior clot), Hydroxyurea resistance or intolerance, Progression to myelofibrosis.
- Transplant and cell therapy teamNamed in the standard of care for: Hydroxyurea resistance or intolerance, Progression to myelofibrosis.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Observation alone in very low risk (under 60, no clot, JAK2-negative); low-dose aspirin for low risk and for anyone with microvascular symptoms, once acquired von Willebrand deficiency is excluded at very high platelet counts.
Cytoreduction to a platelet count under 400 x 10^9/L: hydroxyurea first line (PT-1), pegylated or ropeginterferon alfa-2b preferred under 60 and in pregnancy, anagrelide second line.
Managed as myelofibrosis: JAK inhibitors for spleen and symptoms, transplant for fit higher-risk patients.
Switch to interferon or anagrelide; ruxolitinib did not beat best available therapy in MAJIC-ET but relieves symptoms.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Platelet count above 450 x 10^9/L, JAK2 V617F, CALR exon 9 and MPL W515 mutations, IPSET-thrombosis score, Marrow histology to exclude prefibrotic myelofibrosis, Acquired von Willebrand deficiency at platelet counts above 1,000 x 10^9/L), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include JAK2 V617F-mutated, CALR-mutated, MPL-mutated.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Diagnosis
- For my situation (diagnosis), which of the standard options do you recommend and why?Guideline options include: Full blood count, JAK2, CALR and MPL testing, bone marrow biopsy to confirm ET and exclude prefibrotic myelofibrosis, and exclusion of reactive causes (iron deficiency, inflammation, infection, splenectomy).
Very low and low risk
- For my situation (very low and low risk), which of the standard options do you recommend and why?Guideline options include: Observation alone in very low risk (under 60, no clot, JAK2-negative); low-dose aspirin for low risk and for anyone with microvascular symptoms, once acquired von Willebrand deficiency is excluded at very high platelet counts.
- Am I a candidate for Aspirin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
High risk (over 60 with JAK2 or prior clot)
- For my situation (high risk (over 60 with jak2 or prior clot)), which of the standard options do you recommend and why?Guideline options include: Cytoreduction to a platelet count under 400 x 10^9/L: hydroxyurea first line (PT-1), pegylated or ropeginterferon alfa-2b preferred under 60 and in pregnancy, anagrelide second line.
- Am I a candidate for Hydroxyurea (hydroxycarbamide), Ropeginterferon alfa-2b, Anagrelide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of PT-1 (Primary Thrombocythaemia 1) apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Hydroxyurea resistance or intolerance
- For my situation (hydroxyurea resistance or intolerance), which of the standard options do you recommend and why?Guideline options include: Switch to interferon or anagrelide; ruxolitinib did not beat best available therapy in MAJIC-ET but relieves symptoms.
- Am I a candidate for Anagrelide, Ruxolitinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of MAJIC-ET apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Progression to myelofibrosis
- For my situation (progression to myelofibrosis), which of the standard options do you recommend and why?Guideline options include: Managed as myelofibrosis: JAK inhibitors for spleen and symptoms, transplant for fit higher-risk patients.
- Am I a candidate for Ruxolitinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Bomedemstat, Ropeginterferon alfa-2b?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No treatment has been shown to prevent progression to myelofibrosis or leukaemia”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Very low-risk patients receive nothing and low-risk patients aspirin, but the evidence for aspirin in CALR-mutated low-risk disease is thin and bleeding may outweigh benefit”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Essential thrombocythaemia (ET): the full pageEssential thrombocythaemia is a slow blood cancer in which the marrow makes too many platelets. Most people need only aspirin and monitoring; those at higher risk of clots take a drug to lower the platelet count, usually hydroxyurea or interferon, with anagrelide in reserve.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- JAK2 V617F: A single letter change in the JAK2 gene that jams the growth signal for blood cells in the on position.
- Post-PV myelofibrosis (spent phase): The late stage some people with polycythaemia vera reach after many years, when the marrow scars over, the red count falls and the spleen swells.
- Erythromelalgia: Burning pain, redness and heat in the hands or feet, brought on by warmth.
Every term links to the glossary.